Study type

Study topic

Human medicinal product
Disease /health condition

Study type

Non-interventional study

Scope of the study

Safety study (incl. comparative)
Other

If ‘other’, further details on the scope of the study

Additional data on post-marketing use of Cresemba in Indian patients

Data collection methods

Secondary use of data
Non-interventional study

Non-interventional study design

Other

Non-interventional study design, other

Single-arm, multicenter, observational study
Study drug and medical condition

Name of medicine

CRESEMBA

Medical condition to be studied

Aspergillus infection
Mucormycosis
Population studied

Short description of the study population

Patients aged 18 years or older diagnosed with invasive aspergillosis/invasive mucormycosis treated with isavuconazole (Cresemba).
Inclusion criteria:
1. Patients 18 years or older
2. Patients with diagnosis of invasive aspergillosis/invasive mucormycosis meeting the criteria for proven, probable or possible invasive mould disease as per the judgement of the treating physician and must have received Cresemba for at least 48h .

Exclusion criteria:
There are no other exclusion criteria for this study.

Age groups

Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Special population of interest

Renal impaired
Hepatic impaired
Immunocompromised
Pregnant women

Estimated number of subjects

70
Study design details

Main study objective

To describe a case series of patients treated with Isavuconazole (Cresemba) (post approval) for Invasive Mould Infections (Invasive Aspergillosis, Invasive Mucormycosis) in India during a period of two years (post protocol approval)

Data analysis plan

Descriptive statistics on the study population. Data will be analyzed using standard statistical methods: variables will be described with medians interquartile ranges (IQR), and data analysis will be performed using SPSS software.
Documents
Study results
English (893.79 KB - PDF)View document